Novo Integrated Sciences Operating Margin 2012-2024 | NVOS
Current and historical operating margin for Novo Integrated Sciences (NVOS) over the last 10 years. The current operating profit margin for Novo Integrated Sciences as of August 31, 2024 is 0.00%.
| Novo Integrated Sciences Operating Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Operating Income | Operating Margin |
| 2024-08-31 | $0.01B | $-0.01B | -84.62% |
| 2024-05-31 | $0.01B | $-0.01B | -84.62% |
| 2024-02-29 | $0.01B | $-0.01B | -69.23% |
| 2023-11-30 | $0.01B | $-0.01B | -69.23% |
| 2023-08-31 | $0.01B | $-0.01B | -66.67% |
| 2023-05-31 | $0.00B | $-0.03B | -2500.00% |
| 2023-02-28 | $0.01B | $-0.03B | -208.33% |
| 2022-11-30 | $0.01B | $-0.03B | -208.33% |
| 2022-08-31 | $0.01B | $-0.02B | -200.00% |
| 2022-05-31 | $0.02B | $-0.01B | -26.09% |
| 2022-02-28 | $0.01B | $-0.01B | -45.45% |
| 2021-11-30 | $0.01B | $0.00B | -40.00% |
| 2021-08-31 | $0.01B | $0.00B | -44.44% |
| 2021-05-31 | $0.01B | $-0.01B | -75.00% |
| 2021-02-28 | $0.01B | $-0.01B | -85.71% |
| 2020-11-30 | $0.01B | $-0.01B | -71.43% |
| 2020-08-31 | $0.01B | $0.00B | -50.00% |
| 2020-05-31 | $0.01B | 0 | 0.00% |
| 2020-02-29 | $0.01B | 0 | 0.00% |
| 2019-11-30 | $0.01B | 0 | 0.00% |
| 2019-08-31 | $0.01B | 0 | 0.00% |
| 2019-05-31 | $0.01B | 0 | 0.00% |
| 2019-02-28 | $0.01B | 0 | 0.00% |
| 2018-11-30 | $0.01B | $0.00B | -12.50% |
| 2018-08-31 | $0.01B | $0.00B | -12.50% |
| 2018-05-31 | $0.01B | $0.00B | -37.50% |
| 2018-02-28 | $0.01B | $0.00B | -37.50% |
| 2017-08-31 | $0.01B | $0.00B | -33.33% |
| 2016-11-30 | $0.00B | 0 | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $0.000B | $0.013B |
| Novo Integrated Sciences Inc. is a provider of multi-dimensional primary healthcare services and products principally in Canada and the U.S. It deliver or intend to deliver, multidisciplinary primary health care related services and products through the integration of medical technology, advanced therapeutics and rehabilitative science, through its subsidiaries. Novo Integrated Sciences Inc. is based in Bellevue, Washington. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fresenius SE (FSNUY) | Germany | $29.514B | 13.37 |
| Quest Diagnostics (DGX) | United States | $21.197B | 19.44 |
| Elanco Animal Health (ELAN) | United States | $11.500B | 24.35 |
| Encompass Health (EHC) | United States | $10.662B | 19.64 |
| DaVita (DVA) | United States | $10.023B | 13.82 |
| Chemed (CHE) | United States | $5.639B | 19.57 |
| Option Care Health (OPCH) | United States | $4.553B | 18.71 |
| RadNet (RDNT) | United States | $4.302B | 142.13 |
| LifeStance Health (LFST) | United States | $2.495B | 320.00 |
| Addus HomeCare (ADUS) | United States | $1.719B | 16.61 |
| Astrana Health (ASTH) | United States | $1.536B | 31.40 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.353B | 12.20 |
| U.S Physical Therapy (USPH) | United States | $1.157B | 29.19 |
| Pennant (PNTG) | United States | $1.072B | 31.31 |
| Daxor (DXR) | United States | $0.048B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.032B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |